[{"NetIncomeLoss_1_Q2_USD":-60590000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":114000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-407000.0,"OperatingLeaseLiability_0_Q2_USD":27660000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"ConvertibleLongTermNotesPayable_0_Q2_USD":174304000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":54062678.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":54257320.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":22245000.0,"DerivativeLiabilitiesCurrent_0_Q2_USD":3101000.0,"PaymentsToAcquireShortTermInvestments_2_Q2_USD":159412000.0,"OperatingCostsAndExpenses_2_Q2_USD":118422000.0,"OperatingCostsAndExpenses_1_Q2_USD":57404000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":117000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":1050000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-11674000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":5557000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":25366000.0,"ShareBasedCompensation_2_Q2_USD":13897000.0,"Assets_0_Q2_USD":576181000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":470167000.0,"CommonStockSharesIssued_0_Q2_shares":57313556.0,"AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2_Q2_USD":108510000.0,"Liabilities_0_Q2_USD":320463000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":5464000.0,"InterestExpenseDebtExcludingAmortization_2_Q2_USD":1901000.0,"ResearchAndDevelopmentInProcess_2_Q2_USD":11184000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":29606000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":50830000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-240000.0,"AssetsCurrent_0_Q2_USD":502771000.0,"InterestExpenseDebtExcludingAmortization_1_Q2_USD":1258000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":1222271000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":363511000.0,"CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1_Q2_USD":21000.0,"ShortTermInvestments_0_Q2_USD":130532000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":3372000.0,"IncreaseDecreaseInOtherNoncurrentAssets_2_Q2_USD":-30000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":66897000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":27103000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":39294000.0,"NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_2_Q2_USD":159000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-260000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-134000.0,"AccountsReceivableNetCurrent_0_Q2_USD":49000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":100000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"CommonStockValue_0_Q2_USD":57000.0,"Revenues_2_Q2_USD":357000.0,"Revenues_1_Q2_USD":299000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":2152000.0,"OtherAssetsNoncurrent_0_Q2_USD":1639000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":674000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":674000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-1099000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-60997000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-122409000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":23871000.0,"IncreaseDecreaseInInventories_2_Q2_USD":778000.0,"InvestmentIncomeNonoperating_1_Q2_USD":964000.0,"InvestmentIncomeNonoperating_2_Q2_USD":2455000.0,"PaymentsOfStockIssuanceCosts_2_Q2_USD":337000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":264847000.0,"RevenueRemainingPerformanceObligation_0_Q2_USD":31000000.0,"NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2_Q2_USD":43400000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":494000000.0,"CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_2_Q2_USD":21000.0,"PaymentsForDerivativeInstrumentFinancingActivities_2_Q2_USD":28865000.0,"ConvertibleDebtFairValueDisclosures_0_Q2_USD":285000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":192671000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":49000.0,"ProceedsFromConvertibleDebt_2_Q2_USD":287500000.0,"CommonStockSharesOutstanding_0_Q2_shares":57313556.0,"AmortizationOfFinancingCosts_2_Q2_USD":134000.0,"AmortizationOfFinancingCosts_1_Q2_USD":90000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":117000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":1512000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-60502000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2_Q2_USD":16969000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":6942000.0,"LiabilitiesCurrent_0_Q2_USD":47993000.0,"AccountsPayableCurrent_0_Q2_USD":6603000.0,"PaymentsOfDebtIssuanceCosts_2_Q2_USD":9190000.0,"InterestExpense_2_Q2_USD":6404000.0,"InterestExpense_1_Q2_USD":4256000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":364561000.0,"NetIncomeLoss_2_Q2_USD":-122523000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":13695000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"IncomeLossAttributableToParent_1_Q2_USD":-60590000.0,"IncomeLossAttributableToParent_2_Q2_USD":-122423000.0,"OperatingLeasePayments_2_Q2_USD":3363000.0,"LeaseCost_1_Q2_USD":1697000.0,"NumberOfOperatingSegments_2_Q2_segment":1.0,"OtherIntangibleAssetsNet_0_Q2_USD":31660000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.12,"InterestExpenseDebt_1_Q2_USD":4257000.0,"InterestExpenseDebt_2_Q2_USD":6405000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":1670000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":7901000.0,"PaymentsToAcquireIntangibleAssets_2_Q2_USD":118000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"LeaseCost_2_Q2_USD":3199000.0,"VariableLeaseCost_1_Q2_USD":272000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":11634000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":5733000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":1179000.0,"CommonStockSharesAuthorized_0_Q2_shares":95000000.0,"OperatingIncomeLoss_2_Q2_USD":-118065000.0,"OperatingIncomeLoss_1_Q2_USD":-57105000.0,"OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_2_Q2_USD":0.0,"InventoryNet_0_Q2_USD":778000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":12255000.0,"PreferredStockValue_0_Q2_USD":0.0,"OperatingLeaseCost_2_Q2_USD":2850000.0,"OperatingLeaseCost_1_Q2_USD":1425000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":576181000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":13897000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":7353000.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":4370000.0,"VariableLeaseCost_2_Q2_USD":349000.0,"AmortizationOfFinancingCostsAndDiscounts_2_Q2_USD":4504000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_2_Q2_USD":132000000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":1111000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":470050000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":1113000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-966727000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":74295000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.12,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-2.27,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":0.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":4052000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":3789000.0,"AmortizationOfDebtDiscountPremium_1_Q2_USD":2909000.0,"StockholdersEquity_0_Q2_USD":255718000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":30692000.0,"Ticker":"RVNC","CIK":"1479290","name":"REVANCE THERAPEUTICS, INC.","OfficialName":"Revance Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1265045755.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]